You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
绿叶制药(02186.HK)力扑素及希美纳获《中国食管癌放射治疗指南(2019版)》推荐
格隆汇 09-16 19:13

格隆汇9月16日丨绿叶制药(02186.HK)发布公告,集团的创新紫杉醇脂质体制剂—力扑素和集团1类创新药物注射用甘氨双唑钠—希美纳同获《中国食管癌放射治疗指南(2019版)》推荐。

指南提出,在常用化疗方案中,紫杉醇脂质体与紫杉醇可以互换,并推荐紫杉醇(紫杉醇脂质体)联合其他药物在内的多种方案为新辅助化疗╱新辅助放化疗、根治性放化疗、姑息性放化疗、术后放疗╱放化疗等多项治疗手段的首选方案。

基于充分的循证医学证据,指南在放疗增敏剂中提出注射用甘氨双唑钠是一种高效低毒的放疗增敏剂,推荐其联合放疗,同步放化疗应用于食管癌的治疗。指南由中国医师协会放射肿瘤治疗医师分会、中华医学会放射肿瘤治疗分会及中国抗癌协会肿瘤放射治疗专业委员会等三大学会共同制定。

力扑素为集团的专利制备紫杉醇类制剂,运用创新的脂质体给药剂,用于若干类癌症的化学治疗。根据IQVIA的资料,2019年上半年,中国肿瘤科药品的市场总值为人民币298亿元;以及按收入计算,力扑素为2019年上半年中国最普遍采用的国内抗癌药品,同时亦为2019年上半年中国最普遍采用的紫杉醇类产品。截至2019年6月30日,力扑素为首个及唯一获批准全球销售的紫杉醇类脂质体产品。

希美纳为甘氨双唑钠(集团的专利注射用化合物),用于配合若干实体肿瘤的放射治疗。希美纳为一类新化学药品,且为中国唯一获国家药品监督管理局批准用于癌症放射治疗的敏化剂。根据国家药品监督管理局的资料,于2019年上半年,希美纳为唯一上市的甘氨双唑钠产品。根据2009年的一项独立第三方研究结果,使用希美纳?治疗若干类癌症可以增加完全或部分缓解这些癌症患者病情的概率,并降低整体的治疗成本。

董事会相信,力扑素和希美纳共同获得指南推荐代表这两个产品在临床应用上获得高度认可,并将显着提升产品在相关适应症上的渗透率,为两个产品的长期增长注入动力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account